Washington, DC – September 21, 2016 – Cooley serves as Tobira Therapeutics' intellectual property counsel and acted as such, performing IP diligence on its behalf, for its sale to Allergan for up to $1.7 billion. The price was approximately 19x Tobira’s value at the time of the deal.
"I am extremely excited to see Tobira and Allergan come together," said Laurent Fischer, MD, CEO, Tobira Therapeutics in a company issued press release. "The combination of our team's innovation in the NASH (non-alcoholic steatohepatitis) space and the infrastructure, development expertise and world-class ability of Allergan to market medicines will enable us to more rapidly develop and commercialize needed medications for patients suffering from NASH and other serious fibrotic diseases around the world."
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for NASH and other liver diseases. Allergan focuses on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products.
Cooley has the largest life sciences patent team in the US and is routinely tapped to handle the IP diligence aspects of high-value investments, M&A deals, capital market offerings and other transactions.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.